Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
43.32
+2.42 (5.92%)
Apr 29, 2026, 3:04 PM CST
SHE:300584 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 71.23 | 66.19 | 45.76 | 46.82 | 95.07 | 115.6 |
Cash & Short-Term Investments | 71.23 | 66.19 | 45.76 | 46.82 | 95.07 | 115.6 |
Cash Growth | 39.02% | 44.65% | -2.27% | -50.75% | -17.76% | 2.09% |
Accounts Receivable | 212.25 | 220.15 | 200.56 | 207.7 | 190.71 | 113.31 |
Other Receivables | 0.44 | 0.2 | 0.08 | 0.13 | 18.24 | 10.48 |
Receivables | 212.69 | 220.35 | 200.64 | 207.82 | 208.95 | 123.79 |
Inventory | 85.8 | 76.58 | 85.67 | 81.46 | 64.13 | 55.16 |
Prepaid Expenses | - | - | - | - | 0.23 | 0.23 |
Other Current Assets | 14.02 | 21.2 | 25.08 | 41.19 | 9.99 | 7.17 |
Total Current Assets | 383.74 | 384.32 | 357.15 | 377.3 | 378.38 | 301.96 |
Property, Plant & Equipment | 869.1 | 863.59 | 763.73 | 646.76 | 505.53 | 370.75 |
Long-Term Investments | 111.8 | 113.27 | 131.46 | 131.46 | 190.7 | 437.58 |
Other Intangible Assets | 112.47 | 119.25 | 140.8 | 126.77 | 134.01 | 122.33 |
Long-Term Deferred Tax Assets | 35.84 | 30.98 | 25.49 | 21.84 | 16.6 | 11.76 |
Long-Term Deferred Charges | 3.73 | 2.66 | 10.6 | 41.54 | 37.32 | 50.59 |
Other Long-Term Assets | 15.1 | 18.01 | 35.31 | 63.21 | 31.4 | 7.04 |
Total Assets | 1,532 | 1,532 | 1,465 | 1,409 | 1,294 | 1,302 |
Accounts Payable | 51.74 | 62.28 | 33.74 | 63.95 | 59.89 | 80.26 |
Accrued Expenses | 1.28 | 4.35 | 31.83 | 28.61 | 20.81 | 17.05 |
Short-Term Debt | 210.5 | 188.43 | 230.26 | 252.98 | 120.1 | 100.11 |
Current Portion of Long-Term Debt | 38.99 | 44.57 | 12.18 | 18.02 | 58.06 | 80.09 |
Current Portion of Leases | - | - | - | - | - | 0.08 |
Current Income Taxes Payable | 23.13 | 34.95 | 2.12 | 5.38 | 17.16 | 0.98 |
Current Unearned Revenue | 1.69 | 1.07 | 2.35 | 3.36 | 1.74 | 7.21 |
Other Current Liabilities | 32.45 | 33.29 | 22.88 | 27.97 | 39.29 | 15.64 |
Total Current Liabilities | 359.8 | 368.94 | 335.35 | 400.27 | 317.05 | 301.43 |
Long-Term Debt | 46.71 | 53 | 72.3 | - | - | - |
Long-Term Leases | - | 0.74 | - | - | - | - |
Long-Term Unearned Revenue | 5.94 | 6 | 6.24 | 6.48 | 8.48 | 10.64 |
Long-Term Deferred Tax Liabilities | 3.21 | 3.58 | 12.48 | 14.62 | 17.85 | 41.47 |
Total Liabilities | 415.66 | 432.26 | 426.37 | 421.37 | 343.38 | 353.53 |
Common Stock | 120 | 120 | 120 | 120 | 120 | 120 |
Additional Paid-In Capital | 212.34 | 212.34 | 211.49 | 210.29 | 210.29 | 212.46 |
Retained Earnings | 738.13 | 720.77 | 690.71 | 656.49 | 620.17 | 617.72 |
Comprehensive Income & Other | 0.13 | 0.17 | 0.74 | 0.72 | 0.11 | 0.14 |
Total Common Equity | 1,071 | 1,053 | 1,023 | 987.5 | 950.57 | 950.33 |
Minority Interest | 45.54 | 46.56 | 15.24 | - | - | -1.85 |
Shareholders' Equity | 1,116 | 1,100 | 1,038 | 987.5 | 950.57 | 948.48 |
Total Liabilities & Equity | 1,532 | 1,532 | 1,465 | 1,409 | 1,294 | 1,302 |
Total Debt | 296.2 | 286.73 | 314.74 | 271 | 178.15 | 180.28 |
Net Cash (Debt) | -224.97 | -220.54 | -268.98 | -224.18 | -83.09 | -64.68 |
Net Cash Per Share | -1.87 | -1.84 | -2.24 | -1.87 | -0.69 | -0.54 |
Filing Date Shares Outstanding | 119.99 | 119.95 | 120 | 120 | 120 | 120 |
Total Common Shares Outstanding | 119.99 | 119.95 | 120 | 120 | 120 | 120 |
Working Capital | 23.95 | 15.38 | 21.8 | -22.97 | 61.33 | 0.53 |
Book Value Per Share | 8.92 | 8.78 | 8.52 | 8.23 | 7.92 | 7.92 |
Tangible Book Value | 958.12 | 934.02 | 882.13 | 860.73 | 816.55 | 828 |
Tangible Book Value Per Share | 7.98 | 7.79 | 7.35 | 7.17 | 6.80 | 6.90 |
Buildings | - | - | 252.62 | 251.11 | 251.11 | 241.79 |
Machinery | - | - | 172.2 | 227.36 | 230.08 | 189.93 |
Construction In Progress | - | - | 551.83 | 381.52 | 206.08 | 95.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.